Clemastine
- Generic Name
- Clemastine
- Brand Names
- Wal-hist 12 Hr Relief
- Drug Type
- Small Molecule
- Chemical Formula
- C21H26ClNO
- CAS Number
- 15686-51-8
- Unique Ingredient Identifier
- 95QN29S1ID
- Background
An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness.
- Indication
For the relief of symptoms associated with allergic rhinitis such as sneezing, rhinorrhea, pruritus and acrimation. Also for the management of mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Used as self-medication for temporary relief of symptoms associated with the common cold.
- Associated Conditions
- Allergic Rhinitis (AR), Angioedema, Common Cold, Urticaria
Effect of Clemastine Fumarate on Color Vision in Healthy Controls
- First Posted Date
- 2015-11-24
- Last Posted Date
- 2016-11-03
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 23
- Registration Number
- NCT02613091
- Locations
- 🇺🇸
Sandler Neurosciences Building, Neurological Clinical Research Unit, San Francisco, California, United States
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- First Posted Date
- 2015-08-13
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 90
- Registration Number
- NCT02521311
- Locations
- 🇺🇸
University of California San Francisco, San Francisco, California, United States
Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-01-20
- Last Posted Date
- 2021-10-18
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 50
- Registration Number
- NCT02040298
- Locations
- 🇺🇸
UCSF Multiple Sclerosis Center, San Francisco, California, United States
To Demonstrate the Relative Bioequivalency Study of Dosage Forms of Clemastine 2.68 mg Tablets
- Conditions
- Allergy
- Interventions
- First Posted Date
- 2009-06-04
- Last Posted Date
- 2017-03-28
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 36
- Registration Number
- NCT00913549
Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic Urticaria
- Conditions
- Chronic Urticaria
- Interventions
- First Posted Date
- 2007-06-04
- Last Posted Date
- 2011-10-21
- Lead Sponsor
- Novartis
- Target Recruit Count
- 49
- Registration Number
- NCT00481676
- Locations
- 🇩🇪
Novartis Investigative Site, Munich, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.